
    
      This will be a randomized, placebo-controlled, parallel-group clinical trial. Nondiabetic,
      overweight and obese adult smokers will be randomized to one of three arms:

        -  lorcaserin for 24 weeks in combination with varenicline for 12 weeks;

        -  placebo for 24 weeks in combination with varenicline for 12 weeks;

      We will assess the following:

        -  changes in weight and Weight Concern

        -  7-day point-prevalence smoking abstinence weekly through week 24 and prolonged smoking
           abstinence at 24 and 52 weeks. Subjects will have a target quit date 8 days after
           starting medication.
    
  